Comparison · NCT04620733-sae
Seladelpar vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Seladelpar vs Placebo: serious adverse events. Trial comparisons, record NCT04620733-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04620733-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0703 | 0.0374 | 0.128 | wilson | |
| Risk in group 2 | 0.0615 | 0.0242 | 0.148 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00877 | -0.0836 | 0.0777 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.14 | 0.366 | 3.57 | log | |
| Odds ratio, group 1 over group 2 | 1.15 | 0.341 | 3.9 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Seladelpar than on Placebo | 114 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Seladelpar | Participants received seladelpar 10 mg, orally, once daily, for a duration of up to 12 months. | 9 | 128 | EG001 |
| Group 2 | Placebo | Participants received placebo to match seladelpar, orally, once daily, for a duration of up to 12 months. | 4 | 65 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- All-cause mortality: Up to 20.6 months; Adverse events: Up to last dose plus 30 days (Up to 13.4 months)
Source ClinicalTrials.gov
Trial
- Title
- RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
- NCT number
- NCT04620733
- Phases
- PHASE3
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Seladelpar 10 mg, Placebo, Seladelpar 5 mg
- Lead sponsor
- Gilead Sciences
- Results first posted
- 2024-07-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04620733?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04620733-sae